A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
Niels Daniël PrinsJohn E HarrisonHui-May ChuKelly BlackburnJohn J AlamPhilip Scheltensnull nullPublished in: Alzheimer's research & therapy (2021)
ClinicalTrials.gov identifier: NCT03402659 . Registered on January 18, 2018.